Hutchmed, a biopharmaceutical company controlled by Li Ka-shing, is divesting a 45% stake in a cardiovascular joint venture for $608 million to focus on its core cancer business. The move is expected to boost capital and propel development in targeted cancer therapies.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing